Sugi Predict

Sugi Predict / Compounds / SCHEMBL4339710

SCHEMBL4339710

SCHEMBL4339710

Cc1cccc(-c2[nH]c(C34CCC(C(N)=O)(CC3)CC4)nc2-c2ccc3c(c2)OCO3)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 20/20 1.00
▸ ACVR1B P36896 3/20 0.59
▸ MAPK14 Q16539 2/20 0.59
▸ RIPK2 O43353 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.47
▸ PRKD3 O94806 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TGFBR2 P37173 1/20 0.47
▸ CSNK1A1 P48729 1/20 0.47
▸ CSNK1D P48730 1/20 0.47
▸ CSNK1E P49674 1/20 0.47
▸ RPS6KA1 Q15418 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29504100 1.00 TGFBR1 (1.00) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL376161 0.93 TGFBR1 (0.86) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL30194941 0.93 TGFBR1 (0.86) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4337168 0.92 TGFBR1 (0.85) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4339309 0.90 TGFBR1 (0.82) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4343602 0.90 TGFBR1 (0.81) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4339182 0.89 TGFBR1 (0.81) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4340190 0.89 TGFBR1 (0.81) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4337360 0.89 TGFBR1 (0.81) TGFBR1ACVR1BMAPK14RIPK2TDP1
SCHEMBL4348678 0.88 TGFBR1 (0.78) TGFBR1ACVR1BMAPK14RIPK2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070916-A Application of arteannuin with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 2026-05-22 — — CN claimed
WO-2026103625-A1 METHOD FOR CONSTRUCTING THYMUS ORGANOID AND USE THEREOF 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 2026-05-21 — — WO claimed
CN-122038274-A Method for inducing differentiation and maturation of alveolar organoids and application thereof 广州国家实验室 2026-05-15 — — CN claimed
CN-122038284-A Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof 广州国家实验室 2026-05-15 — — CN claimed
US-20250339520-A1 COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-11-06 — — US claimed
CN-119614476-A Construction method and application of thymus organoids 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 2025-03-14 — — CN claimed
WO-2025037115-A1 A METHOD OF DIAGNOSING AND/OR DIFFERENTIATING A NEUROLOGICAL DISORDER VESALIC LIMITED (A COMPANY REGISTERED IN ENGLAND UNDER COMPANY NUMBER 14684070) (GB) 2025-02-20 — — WO claimed
CN-119432743-A Kit for inducing stem cells to differentiate into motor nerve precursor cells and/or motor neurons and application of kit 士泽生物医药（苏州）有限公司 2025-02-14 — — CN claimed
CN-119351337-A Exosomes derived from stem cell differentiation cells and preparation method thereof 士泽生物医药(上海)有限公司 2025-01-24 — — CN claimed
CN-114096557-B Production of dorsal foregut and anterior endoderm cells 克利夫兰诊所基金会 2024-12-13 — — CN claimed
CN-114540278-A Microvessel in-vitro culture method and culture solution 青岛大学 2022-05-27 — — CN claimed
EP-3972990-A1 GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS The Cleveland Clinic Foundation (US) 2022-03-30 — — EP claimed
CN-114096557-A Generation of germ layer cells in the dorsal foregut and anterior structural domains 克利夫兰诊所基金会 2022-02-25 — — CN claimed
US-7612094-B2 Tri-substituted heteroaryls and methods of making and using the same BIOGEN IDEC MA INC. (US) 2009-11-03 — — US claimed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 — — WO claimed
EP-1804801-A2 METHODS OF TREATING VASCULAR INJURIES Biogen Idec MA, Inc. (US) 2007-07-11 — — EP claimed
WO-2006044509-A2 METHODS OF TREATING VASCULAR INJURIES BIOGEN IDEC MA INC. (US) 2006-04-27 — — WO claimed
US-20060063809-A1 Tri-substituted heteroaryls and methods of making and using the same BIOGEN MA INC. 2006-03-23 — — US claimed
EP-1499308-A2 TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME BIOGEN, INC. (US) 2005-01-26 — — EP claimed
WO-2003087304-A2 TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME BIOGEN, INC. (US) 2003-10-23 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063809-A1 Tri-substituted heteroaryls and methods of making and using the same ALK, ACVR1, ACVRL1 TGFBR1 13/4885ACVR1B 6/4885MAPK14 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.